ME Therapeutics Holdings Inc.
METX
CNSX
| 05/31/2025 | 02/28/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 55.85% | -52.89% | |||
| Depreciation & Amortization | 27.97% | 88.16% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 79.25% | -36.29% | |||
| Operating Income | -79.25% | 36.29% | |||
| Income Before Tax | -79.96% | 36.24% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -79.96% | 36.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -79.96% | 36.24% | |||
| EBIT | -79.25% | 36.29% | |||
| EBITDA | -79.02% | 38.03% | |||
| EPS Basic | -63.46% | 40.23% | |||
| Normalized Basic EPS | -60.61% | 38.89% | |||
| EPS Diluted | -21.43% | 19.54% | |||
| Normalized Diluted EPS | -60.61% | 38.89% | |||
| Average Basic Shares Outstanding | 10.27% | 6.53% | |||
| Average Diluted Shares Outstanding | 10.27% | 6.53% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||